JANSSEN BIOTECH INC has a total of 2,623 patent applications. It decreased the IP activity by 30.0%. Its first patent ever was published in 2001. It filed its patents most often in United States, EPO (European Patent Office) and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are SYNERGEN BIOLOG INC, ALBUMEDIX AS and ALFACELL CORP.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 354 | |
#2 | EPO (European Patent Office) | 282 | |
#3 | WIPO (World Intellectual Property Organization) | 239 | |
#4 | Australia | 222 | |
#5 | Republic of Korea | 157 | |
#6 | China | 148 | |
#7 | Canada | 139 | |
#8 | Israel | 108 | |
#9 | Brazil | 98 | |
#10 | Mexico | 98 | |
#11 | Singapore | 93 | |
#12 | Japan | 63 | |
#13 | Taiwan | 59 | |
#14 | Argentina | 56 | |
#15 | Philippines | 54 | |
#16 | Hong Kong | 50 | |
#17 | South Africa | 45 | |
#18 | EAPO (Eurasian Patent Organization) | 26 | |
#19 | Uruguay | 26 | |
#20 | New Zealand | 25 | |
#21 | Chile | 24 | |
#22 | Hungary | 24 | |
#23 | Peru | 24 | |
#24 | Ecuador | 23 | |
#25 | Serbia | 21 | |
#26 | Nicaragua | 19 | |
#27 | Costa Rica | 18 | |
#28 | Ukraine | 16 | |
#29 | Colombia | 14 | |
#30 | Guatemala | 12 | |
#31 | Jordan | 12 | |
#32 | El Salvador | 11 | |
#33 | Dominican Republic | 8 | |
#34 | Norway | 8 | |
#35 | Russian Federation | 8 | |
#36 | Slovenia | 8 | |
#37 | Luxembourg | 6 | |
#38 | India | 5 | |
#39 | Lithuania | 4 | |
#40 | Montenegro | 4 | |
#41 | Malaysia | 4 | |
#42 | United Kingdom | 3 | |
#43 | Morocco | 2 | |
#44 | Netherlands | 2 | |
#45 | Belgium | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement | |
#4 | Medical technology | |
#5 | Environmental technology | |
#6 | Organic fine chemistry | |
#7 | Foods and drinks |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Peptides | |
#3 | Medical preparations | |
#4 | Microorganisms | |
#5 | Analysing materials | |
#6 | Syringes | |
#7 | Climate change adaptation technologies | |
#8 | Sugars | |
#9 | Measuring microorganism processes | |
#10 | Enzymes |
# | Name | Total Patents |
---|---|---|
#1 | Rezania Alireza | 205 |
#2 | Luo Jinquan | 187 |
#3 | Wu Sheng-Jiun | 175 |
#4 | Teplyakov Alexey | 150 |
#5 | Jacobs Steven | 147 |
#6 | Sweet Raymond | 119 |
#7 | Diem Michael | 109 |
#8 | Wheeler John | 108 |
#9 | O'Neil Karyn | 100 |
#10 | Huang Chichi | 98 |
Publication | Filing date | Title |
---|---|---|
WO2021079315A1 | Steerable needles | |
US2021115129A1 | Safe and Effective Method of Treating Ulcerative Colitis with Anti-IL12/IL23 Antibody | |
WO2021076855A1 | Dynamic monosaccharide control processes | |
WO2021070132A1 | Bi-aryl dihydroorotate dehydrogenase inhibitors | |
WO2021072169A1 | Materials and methods for mass spectrometric protein analysis | |
WO2021064671A1 | Methods for producing biotherapeutics with increased stability by sequence optimization | |
WO2021067191A1 | Compositions and methods for an il-17 target engagement assay with small molecule modulators | |
WO2021067195A1 | Compositions and methods for an il-17 target engagement assay with large molecule modulators | |
WO2021055894A1 | Materials and methods for differential characterization of molecular conjugates and conjugation | |
WO2021059075A1 | Anti-ceacam antibodies and uses thereof | |
US2020392242A1 | Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses | |
WO2021038524A1 | B-cell maturation complex car t construct and primers | |
US2020405854A1 | Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses | |
WO2021038490A1 | Substituted urea dihydroorotate dehydrogenase inhibitors | |
WO2021038474A1 | Tissue anchor and related methods | |
WO2021041486A1 | Chimeric antigen receptor system and uses thereof | |
US2020397896A1 | Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses | |
US2021047435A1 | Materials and methods for improved single chain variable fragments | |
WO2021030657A1 | Materials and methods for improved single chain variable fragments | |
US2021047423A1 | Therapeutic immune cells with improved function and methods for making the same |